Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 8, 2008, Pages 913-919

  Ayuk, Francis ^a   Diyachenko, Galina ^a   Zabelina, Tatjana ^a   Wolschke, Christine ^a   Fehse, Boris ^a   Bacher, Ulrike ^a   Erttmann, Rudolf ^a   Kröger, Nicolaus ^a   Zander, Axel R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ATG; Dose; Stem cell transplantation

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BASILIXIMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PNEUMOCYSTIS PNEUMONIA; RECURRENCE RISK; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; INFANT; INFECTION; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 47249106496     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.05.023     Document Type: Article

References (36)

1. Thomas E.D., Storb R., Clift R., et al. Bone marrow transplantation I and II. N Engl J Med 292 (1975) 832-843
2. O'Reilly R.J. Allogeneic bone marrow transplantation: current status and future directions. Blood 62 (1983) 941-964
3. Thomas E.D., Clift R.A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104 (1986) 155-163
4. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and ciclosporine compared to ciclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
5. Beatty P.G., Ash R., Hows J.M., and McGlave P.B. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant 4 (1989) 287-290
6. Beatty P.G., Hansen J., Longton G.M., et al. Marrow transplantation from HLA-matched unrelated donors for the treatment of hematologic malignancies. Transplantation 51 (1991) 443-447
7. Nademanee A., Schmidt G.M., Parker P., et al. The outcome of matched unrelated donor transplantation in patients with hematological malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of ciclosporine, methotrexate and prednisone. Blood 86 (1995) 1228-1234
8. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 (1993) 593-602
9. Marks D.I., Cullis J.O., Ward K.N., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 119 (1993) 207-214
10. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alles in the donor and recipient. Blood 92 (1998) 3515-3520
11. Sasazuki T., Juji T., Morishima Y., et al. Effect of matching of class I HLA alles on clinical outcome after transplantation of hematopoietic stem cells from an untelated donor. Japan Marrow Donor Program. N Engl J Med 339 (1998) 1177-1185
12. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
13. Young J., Papadopoulos E., Cunningham I., et al. T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 79 (1992) 3380-3387
14. Zander A.R., Zabelina T., Kröger N., et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 23 (1999) 889-893
15. Finke J., Bertz H., Schmoor C., et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T cell globulin. Br J Haematol 111 (2000) 303-313
16. Remberger M., Svahn B.-M., Hentschke P., et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 24 (1991) 823-830
17. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxes in transplants form unrelated donor: 2 randomized studies from Gruppo Italiono Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
18. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
19. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
20. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35 (2005) 225-231
21. Dominietto A., Van Lint M.T., Gualandi F., et al. Is timing of antithymocyte globulin (ATG)- pre and post hemopoetic stem cell transplants (HSCT)-relevant for graft vs host disease?. Blood 102 (2003) 242a (abstract 851)
22. Eiermann T.H., Lambrecht P., and Zander A.R. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 23 (1999) 779-781
23. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21 (2007) 1387-1394
24. Meijer E., Cornelissen J.J., Lowenberg B., and Verdonck L.F. Antithymocyte globulin as prophylaxis of graft-versus-host disease in recipients of partially depleted grafts from matched unrelated donors: a dose finding study. Exp Hematol 31 (2003) 1026-1030
25. Kalwak K., Moson I., Cwian J., et al. A prospective analysis of immune recovery in children following allogeneic transplantation of T-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors. Transplant Proc 35 (2003) 1551-1555
26. Meijer E., Bloem A.C., Dekker A.W., and Verdonk L.F. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell depleted bone marrow transplantation: a comparison of matched related and matched unrelated grafts. Transplantation 75 (2003) 1910-1913
27. Fehse N., Fehse B., Kroger N., et al. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 12 (2003) 237-242
28. Schleuning M., Gunther W., Tischer J., et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 32 (2003) 243-250
29. Helmberg W., Lanzer G., Zahn R., Weinmayr B., Wagner T., and Albert E. Virtual DNA analysis-a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 51 (1998) 587-592
30. Marsh S.G., Albert E.D., Bodmer W.F., et al. Nomenclature for factors of the HLA system. Tissue Antigens 60 (2002) 407-464
31. Robinson J., Walter M.J., Parham P., et al. IMGT/HLA and IMGT/MHC: sequence database for the study of the major histocompatibility complex. Nucleic Acids Res 31 (2003) 311-314
32. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 4 (1974) 295-230
33. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host-syndrome in man, a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
34. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
35. Ramsay N.K.C., Keysey J.H., Robinson L.L., et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306 (1982) 392-397
36. Duggan P., Booth K., Chaudhry A., et al. Alberta Blood and Bone Marrow Transplant Program. Unrelated donor BMT recipients given pretansplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 30 (2002) 681-686